Successful treatment of infantile refractory bullous pemphigoid with baricitinib.

IF 2.2 4区医学 Q2 DERMATOLOGY

Australasian Journal of Dermatology Pub Date : 2024-07-19 DOI:10.1111/ajd.14345

Weinan Zhou, Yidong Tan, Xuanyi Chen, Wenqing Zhang, Zhe Sun, Yihang Shen, Zhirong Yao, Ruhong Cheng, Yan Gu

引用次数: 0

Abstract

Infantile bullous pemphigoid (BP) is a rare autoantibody-mediated skin disorder. We report the effective treatment of a 6-month-old infant with BP using baricitinib, a Janus kinase (JAK) inhibitor, after failure with steroids and intravenous immunoglobulin. The patient achieved full remission and discontinued all medications without any relapses. To our knowledge, this is the first case of baricitinib used in an infant with BP.

查看原文本刊更多论文

巴利替尼成功治疗婴儿难治性大疱性类天疱疮

婴儿大疱性类天疱疮（BP）是一种罕见的自身抗体介导的皮肤疾病。我们报告了使用类固醇和静脉注射免疫球蛋白失败后，使用巴利昔尼（一种 Janus 激酶（JAK）抑制剂）有效治疗一名 6 个月大婴儿丘疹性脓疱疮的病例。患者病情完全缓解，停用所有药物后未再复发。据我们所知，这是首例将巴利替尼用于婴儿肺结核患者的病例。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Australasian Journal of Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

5.00%

发文量

186

审稿时长

6-12 weeks

期刊介绍： Australasian Journal of Dermatology is the official journal of the Australasian College of Dermatologists and the New Zealand Dermatological Society, publishing peer-reviewed, original research articles, reviews and case reports dealing with all aspects of clinical practice and research in dermatology. Clinical presentations, medical and physical therapies and investigations, including dermatopathology and mycology, are covered. Short articles may be published under the headings ‘Signs, Syndromes and Diagnoses’, ‘Dermatopathology Presentation’, ‘Vignettes in Contact Dermatology’, ‘Surgery Corner’ or ‘Letters to the Editor’.